Advanced stem cell therapy for cardiovascular diseases including heart failure and coronary artery disease. Our mesenchymal stem cell treatments help regenerate damaged heart tissue and improve cardiac function naturally.
Cardiovascular disease remains the leading cause of death worldwide. At StemCell Longevita in Istanbul, Turkey, our mesenchymal stem cell (MSC) therapy offers a regenerative approach to heart disease that goes beyond symptom management. Using umbilical cord-derived Wharton's jelly stem cells from our GMP-certified laboratory, we help patients with heart failure, coronary artery disease, cardiomyopathy, and post-heart attack damage restore cardiac function and improve quality of life.
MSC therapy for cardiovascular disease works through multiple mechanisms. Stem cells promote angiogenesis — the formation of new blood vessels — improving blood flow to oxygen-starved heart tissue. They secrete anti-inflammatory cytokines that reduce chronic cardiac inflammation, a key driver of heart failure progression. MSCs also release growth factors that stimulate the repair of damaged myocardium (heart muscle) and reduce harmful scar tissue formation. Studies published in the Journal of the American College of Cardiology demonstrate measurable improvements in left ventricular ejection fraction (LVEF) following MSC infusion.
Ideal candidates for cardiovascular stem cell therapy include patients with heart failure (NYHA class II-IV), reduced ejection fraction, chronic coronary artery disease, post-myocardial infarction damage, or cardiomyopathy. Patients who have not responded adequately to conventional treatments or who wish to avoid or delay surgical interventions may benefit significantly. Our medical team evaluates each patient's cardiac imaging, lab results, and medical history to design a personalized treatment protocol.
Treatment begins with a free remote consultation where our cardiology team reviews your echocardiogram, cardiac MRI, and blood work. Upon arrival in Istanbul, you receive a comprehensive cardiac evaluation. The stem cell procedure involves IV infusion of 50-100 million Wharton's jelly MSCs with 97% viability, administered over 1-3 hours in our JCI-accredited partner hospital. Most patients require 1-2 treatment sessions. The entire Istanbul stay is typically 3-5 days, with hotel accommodation and VIP airport transfers included.
Patients typically report improved energy levels, reduced shortness of breath, better exercise tolerance, and enhanced quality of life within 2-6 months. Echocardiogram improvements — including increased ejection fraction of 5-12% — are often measurable within 3-6 months. Follow-up monitoring at 1, 3, 6, and 12 months tracks your cardiac markers and overall progress.
Istanbul is a global hub for cardiovascular medicine with JCI-accredited hospitals equipped with the latest cardiac imaging and monitoring technology. Our GMP-certified stem cell laboratory ensures the highest quality MSCs. Patients save 60-80% compared to equivalent treatments in the US, UK, or Germany, without compromising on quality or safety.
Cardiovascular stem cell therapy packages at StemCell Longevita start from €6,950, including 50-100M Wharton's jelly MSCs, pre-treatment cardiac evaluation, hotel accommodation, VIP airport transfers, and 12-month remote follow-up. This represents savings of 60-80% compared to comparable treatments in the United States or Western Europe.
Related treatments: Angina Stem Cell Therapy | Ischemic Cardiomyopathy Stem Cell Therapy | Stroke Recovery Stem Cell Therapy
